• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于因果森林的异质治疗效果的可推广性,应用于两项强化血糖控制的随机临床试验。

Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control.

机构信息

Department of Veterans Affairs Eastern Colorado Healthcare System, Aurora, CO; Division of Hospital Medicine, University of Colorado School of Medicine, Aurora, CO; Colorado Cardiovascular Outcomes Research Consortium, Aurora, CO.

Department of Veterans Affairs Eastern Colorado Healthcare System, Aurora, CO; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO.

出版信息

Ann Epidemiol. 2022 Jan;65:101-108. doi: 10.1016/j.annepidem.2021.07.003. Epub 2021 Jul 17.

DOI:10.1016/j.annepidem.2021.07.003
PMID:34280545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8748294/
Abstract

Purpose Machine learning is an attractive tool for identifying heterogeneous treatment effects (HTE) of interventions but generalizability of machine learning derived HTE remains unclear. We examined generalizability of HTE detected using causal forests in two similarly designed randomized trials in type II diabetes patients. Methods We evaluated published HTE of intensive versus standard glycemic control on all-cause mortality from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD) in a second trial, the Veterans Affairs Diabetes Trial (VADT). We then applied causal forests to VADT, ACCORD, and pooled data from both studies and compared variable importance and subgroup effects across samples. Results HTE in ACCORD did not replicate in similar subgroups in VADT, but variable importance was correlated between VADT and ACCORD (Kendall's tau-b 0.75). Applying causal forests to pooled individual-level data yielded seven subgroups with similar HTE across both studies, ranging from risk difference of all-cause mortality of -3.9% (95% CI -7.0, -0.8) to 4.7% (95% CI 1.8, 7.5). Conclusions Machine learning detection of HTE subgroups from randomized trials may not generalize across study samples even when variable importance is correlated. Pooling individual-level data may overcome differences in study populations and/or differences in interventions that limit HTE generalizability.

摘要

目的

机器学习是一种有吸引力的工具,可用于识别干预措施的异质治疗效果(HTE),但机器学习衍生的 HTE 的可推广性尚不清楚。我们在两项设计类似的 2 型糖尿病患者随机试验中检查了因果森林检测到的 HTE 的可推广性。

方法

我们评估了 ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES 研究(ACCORD)中强化与标准血糖控制对全因死亡率的 HTE 在第二项试验——退伍军人事务部糖尿病试验(VADT)中的重复性。然后,我们将因果森林应用于 VADT、ACCORD 以及两项研究的汇总数据,并比较了样本间的变量重要性和亚组效应。

结果

ACCORD 中的 HTE 在 VADT 中类似的亚组中没有复制,但 VADT 和 ACCORD 之间的变量重要性呈正相关(Kendall 的 tau-b 为 0.75)。将因果森林应用于汇总的个体水平数据,在两项研究中产生了七个具有相似 HTE 的亚组,全因死亡率的风险差异范围从-3.9%(95%CI-7.0,-0.8)到 4.7%(95%CI1.8,7.5)。

结论

即使变量重要性相关,从随机试验中机器学习检测到的 HTE 亚组也可能无法推广到研究样本。汇总个体水平数据可能会克服研究人群和/或干预措施的差异,这些差异限制了 HTE 的可推广性。

相似文献

1
Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control.基于因果森林的异质治疗效果的可推广性,应用于两项强化血糖控制的随机临床试验。
Ann Epidemiol. 2022 Jan;65:101-108. doi: 10.1016/j.annepidem.2021.07.003. Epub 2021 Jul 17.
2
Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.强化血糖控制对 ACCORD 和 VADT 试验中主要不良心血管事件的异质性治疗效果:机器学习分析。
Cardiovasc Diabetol. 2022 Apr 27;21(1):58. doi: 10.1186/s12933-022-01496-7.
3
Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial.与 2 型糖尿病和高心血管风险患者的血糖治疗降低或增加死亡率相关的特征:ACCORD 试验的机器学习分析。
Diabetes Care. 2018 Mar;41(3):604-612. doi: 10.2337/dc17-2252. Epub 2017 Dec 26.
4
Intensive glycemic control and cardiovascular disease: an update.强化血糖控制与心血管疾病:最新进展。
Nat Rev Cardiol. 2010 Jul;7(7):369-75. doi: 10.1038/nrcardio.2010.35. Epub 2010 Apr 20.
5
Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT).退伍军人事务糖尿病试验(VADT)中强化血糖控制对肾脏结局的长期随访。
Diabetologia. 2018 Feb;61(2):295-299. doi: 10.1007/s00125-017-4473-2. Epub 2017 Nov 3.
6
Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT.空腹血糖波动预测 ACCORD 和 VADT 中的微血管风险。
J Clin Endocrinol Metab. 2021 Mar 25;106(4):1150-1162. doi: 10.1210/clinem/dgaa941.
7
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.2型糖尿病中的心血管疾病与强化血糖控制:推动实践走向基于证据的策略
Vasc Health Risk Manag. 2009;5:859-71. doi: 10.2147/vhrm.s4808. Epub 2009 Nov 2.
8
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A in the ADVANCE Trial.强化血糖控制对 ADVANCE 试验中不同心血管风险和血红蛋白 A 水平的 2 型糖尿病患者临床结局的影响。
Diabetes Care. 2020 Jun;43(6):1293-1299. doi: 10.2337/dc19-1817. Epub 2020 Mar 19.
9
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.2型糖尿病强化血糖控制期间心血管死亡率的遗传预测因素:ACCORD临床试验的结果
Diabetes Care. 2016 Nov;39(11):1915-1924. doi: 10.2337/dc16-0285. Epub 2016 Aug 15.
10
Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.2型糖尿病血糖控制与并发症合作研究的设计:退伍军人事务部糖尿病试验
J Diabetes Complications. 2003 Nov-Dec;17(6):314-22. doi: 10.1016/s1056-8727(02)00277-5.

引用本文的文献

1
Toward Precision in Critical Care Research: Methods for Observational and Interventional Studies.迈向重症监护研究的精准化:观察性和干预性研究方法。
Crit Care Med. 2024 Sep 1;52(9):1439-1450. doi: 10.1097/CCM.0000000000006371. Epub 2024 Aug 15.
2
A Novel Digital Twin Strategy to Examine the Implications of Randomized Clinical Trials for Real-World Populations.一种用于研究随机临床试验对真实世界人群影响的新型数字孪生策略。
medRxiv. 2024 Sep 6:2024.03.25.24304868. doi: 10.1101/2024.03.25.24304868.
3
Heterogeneous treatment effects of Cerebrolysin as an early add-on to reperfusion therapy: analysis of the CEREHETIS trial.

本文引用的文献

1
Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT.血压变异性与 ACCORD 和 VADT 中的心力衰竭风险。
Diabetes Care. 2020 Jul;43(7):1471-1478. doi: 10.2337/dc19-2540. Epub 2020 Apr 23.
2
Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness.机器学习和人工智能研究如何造福患者:透明度、可重复性、伦理和有效性方面的 20 个关键问题。
BMJ. 2020 Mar 20;368:l6927. doi: 10.1136/bmj.l6927.
3
Challenges to the Reproducibility of Machine Learning Models in Health Care.
脑活素作为再灌注治疗早期附加治疗的异质性治疗效果:CEREHETIS试验分析
Front Pharmacol. 2024 Jan 5;14:1288718. doi: 10.3389/fphar.2023.1288718. eCollection 2023.
4
Precision subclassification of type 2 diabetes: a systematic review.2型糖尿病的精准亚分类:一项系统综述
Commun Med (Lond). 2023 Oct 5;3(1):138. doi: 10.1038/s43856-023-00360-3.
5
Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine.因果森林与基于回归方法比较评估治疗效果异质性:2 型糖尿病精准医学的应用
BMC Med Inform Decis Mak. 2023 Jun 16;23(1):110. doi: 10.1186/s12911-023-02207-2.
6
A permutation procedure to detect heterogeneous treatment effects in randomized clinical trials while controlling the type I error rate.一种在随机临床试验中控制Ⅰ类错误率的同时检测异质治疗效果的排列检验方法。
Clin Trials. 2022 Oct;19(5):512-521. doi: 10.1177/17407745221095855. Epub 2022 May 9.
7
Heterogeneous treatment effects in social policy studies: An assessment of contemporary articles in the health and social sciences.社会政策研究中的异质处理效应:对健康和社会科学领域当代文章的评估。
Ann Epidemiol. 2022 Jun;70:79-88. doi: 10.1016/j.annepidem.2022.04.009. Epub 2022 Apr 26.
8
Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.强化血糖控制对 ACCORD 和 VADT 试验中主要不良心血管事件的异质性治疗效果:机器学习分析。
Cardiovasc Diabetol. 2022 Apr 27;21(1):58. doi: 10.1186/s12933-022-01496-7.
医疗保健领域机器学习模型可重复性面临的挑战。
JAMA. 2020 Jan 28;323(4):305-306. doi: 10.1001/jama.2019.20866.
4
Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy.强化血压治疗个体治疗效果预测的临床价值
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005010. doi: 10.1161/CIRCOUTCOMES.118.005010.
5
Metalearners for estimating heterogeneous treatment effects using machine learning.使用机器学习估计异质处理效应的元学习器。
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4156-4165. doi: 10.1073/pnas.1804597116. Epub 2019 Feb 15.
6
Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals.将随机试验中个体的因果推断推广到所有符合试验条件的个体。
Biometrics. 2019 Jun;75(2):685-694. doi: 10.1111/biom.13009. Epub 2019 Jun 21.
7
The Science of Prognosis in Psychiatry: A Review.精神病学预后的科学:综述。
JAMA Psychiatry. 2018 Dec 1;75(12):1289-1297. doi: 10.1001/jamapsychiatry.2018.2530.
8
Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.基于机器学习的心衰表型分组以识别心脏再同步治疗的反应者。
Eur J Heart Fail. 2019 Jan;21(1):74-85. doi: 10.1002/ejhf.1333. Epub 2018 Oct 17.
9
Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target Population.比较在没有目标人群个体水平数据的情况下推广随机临床试验结果的方法。
Am J Epidemiol. 2019 Feb 1;188(2):426-437. doi: 10.1093/aje/kwy233.
10
Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials.预防随机试验中异质性治疗效果亚组的错误发现。
Trials. 2018 Jul 16;19(1):382. doi: 10.1186/s13063-018-2774-5.